Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive, Asthma
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma
- Trial name
- NCT00152984
- Testing
- Tiotropium inhalation capsules
- Where
- 68 sites in Belgium, Canada and 6 more
- Volunteers
- 472 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol
The purpose of the study is to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily budesonide for 12 weeks in COPD patients on a background therapy of formoterol.
- Trial name
- NCT01555099
- Testing
- AZD5423, Budesonide
- Where
- 44 sites in Bulgaria, France and 6 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
This study is to assess the safety and tolerability of two different doses of QVA149 and QAB149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01682863
- Testing
- QVA149, QAB149
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 614 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Chronic Obstructive Pulmonary Disease
Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers
An open-label, single dose Pharmacokinetic (PK) comparability study to demonstrate comparable drug exposure following Subcutaneous benralizumab administration by using accessorized pre-filled syringe (APFS) or autoinjector (AI)…
- Trial name
- NCT02968914
- Testing
- Benralizumab
- Where
- 2 sites in Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Emphysema
Pilot Study of the Spiration IBV™ System
The Spiration Intra-Bronchial Valve is intended for use as a minimally invasive treatment for severe emphysema, using standard bronchoscopy.
- Trial name
- NCT00145548
- Testing
- Intra Bronchial Valve
- Where
- 14 sites in United States
- Volunteers
- 91 people
- Sponsor
- Olympus Corporation of the Americas
Pulmonary Disease, Chronic Obstructive
To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
The primary objectives of the study are to explore the effect of treatment with orally inhaled tiotropium + olodaterol fixed dose combination with and without exercise training, and tiotropium comparing to placebo, on top of…
- Trial name
- NCT02085161
- Testing
- tiotropium+olodaterol, tiotropium +olodaterol, tiotropium
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 304 people
- Sponsor
- Boehringer Ingelheim
COPD
A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.
- Trial name
- ACROSS (NCT01313494)
- Testing
- Roflumilast, Salbutamol
- Where
- 15 sites in China, Hong Kong and 1 more
- Volunteers
- 626 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)
The aim of this Post Authorisation Safety Study (PASS) is to assess the incidence of adverse cardiovascular and cerebrovascular events in COPD patients who are new to inhaled fixed triple therapy (dual bronchodilator plus…
- Trial name
- TRIBE (NCT05652439)
- Testing
- Observational retrospective data collection
- Where
- United Kingdom
- Volunteers
- 25,000 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The compound GW642444 has previously been found to be well tolerated with no significant side effects in subjects with asthma and healthy volunteers.
- Trial name
- NCT00372112
- Testing
- GW642444
- Where
- 14 sites in Australia, Bulgaria and 4 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Emphysema or COPD
Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema
The goal of this clinical trial is to test the feasibility of an implant for severe emphysema in up to 30 participants at up to 5 study centers located in Europe and the United Kingdom.
- Trial name
- BREATHE-2 (NCT05949645)
- Testing
- Apreo Implant Group
- Where
- 3 sites in Austria, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Apreo Health, Inc.
Asthma
Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled LAS100977 QD in patients with persistent asthma.
- Trial name
- NCT01425801
- Testing
- LAS100977 0.313 μg, LAS100977 0.625 μg, LAS100977 1.25 μg
- Where
- 9 sites in Germany, United Kingdom
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
COPD
Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD
The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation device.
- Trial name
- NCT05799664
- Testing
- TLD, Standard of care
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Hangzhou Broncus Medical Co., Ltd.
Chronic Obstructive Pulmonary Disease
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared…
- Trial name
- NCT02796677
- Testing
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg)
- Where
- 163 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and…
- Trial name
- FAST (NCT01922271)
- Testing
- NVA237, Tiotropium, Salbutamol
- Where
- 14 sites in Germany
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, COPD
Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs
This is a crossover study to assess the systemic pharmacokinetics of fluticasone propionate (FP) and salmeterol (SAL). Study medication will be administered as fixed dose combinations (250 µg FP and 50 µg SAL) from the Advair®…
- Trial name
- NCT02215122
- Testing
- MGR001, Advair® Diskus®, Seretide™ Accuhaler™
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mylan Pharma UK Ltd.
Pulmonary Disease, Chronic Obstructive
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered…
- Trial name
- NCT00400153
- Testing
- Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg)
- Where
- 180 sites in United States, Argentina and 11 more
- Volunteers
- 1,480 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer, Emphysema
CryoSpray Ablation(tm)Thoracic Patient Registry
The purpose of this study is to create a patient registry to collect and analyze information on subjects treated with the CryoSpray Ablation™ System post-510K approval.
- Conditions
- Lung Cancer, Emphysema, Chronic Bronchitis, COPD
- Trial name
- NCT00785239
- Sponsor
- CSA Medical, Inc.
Chronic Obstructive Pulmonary Disease
A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is characterized by a progressive decline in lung function and increased symptoms such as breathlessness/dyspnoea, cough and expectoration.
- Trial name
- COPD Language (NCT01219946)
- Where
- 32 sites in Greece
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)
The study will be conducted in a single-center, randomized, single-blinded, placebo-controlled, dose escalation design with two dose groups.Multiple-dose inhalation of Ciprofloxacin inhale 50 and 75 mg or placebo will be…
- Trial name
- NCT01072942
- Testing
- Ciprofloxacin (Cipro InhaIe, BAYQ3939)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease
Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)
Trial to evaluate the dose response of SCH 527123 in reducing inflammation from an ozone-induced sputum neutrophilia in both healthy subjects and subjects with COPD.
- Trial name
- NCT01068145
- Testing
- SCH 527123
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.